Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Megan E V CaramMary K OerlineStacie B DusetzinaLindsey A HerrelParth K ModiSamuel R KaufmanTed A SkolarusBrent K HollenbeckVahakn ShahinianPublished in: Cancer (2020)
There were substantial variations in the adherence rate and out-of-pocket payments among Medicare Part D beneficiaries who were prescribed abiraterone and enzalutamide. Sociodemographic patient and regional factors were found to be associated with both adherence and out-of-pocket payments.